Is Bangladesh to India what India is to China?

In a twisted way, that’s a question worth asking. At least when it comes to cancer drugs.

India has, for a long time now, been one of the top suppliers of generic drugs in the world. The Indian pharma industry is possibly the largest provider of generic drugs, meeting about 40% of generic drug demand in the US. The drugs are mostly of decent quality and relatively low price, which is a win-win for any buyer out there.

But when it comes to cancer, India is failing its own population, let alone the world.

In July 2018, China agreed to reduce the import tariffs for Indian medicines, specifically cancer drugs. This came days after a hugely-popular dark comedy Chinese movie called Dying to Survive told the story of a man diagnosed with leukaemia who imports cheap cancer drugs from India to China.

While Indian cancer drugs are a cheaper alternative for the Chinese, as irony may have it, not all Indians can afford them. In fact, according to a first-of-its-kind WHO report from December 2018, the price of many oncology drugs in India are as high as in developed countries, taking Indians purchasing power into account.

So what are Indians doing about this? Turning to Bangladesh.

That’s right. The likes of S Distributors, a small-time importer and drug distributor in South Delhi, form the middle ground between Indian cancer patients and cheap cancer drug alternatives from Bangladesh. And it’s a bit hard to not draw parallels between their business and the plot of Dying to Survive.

What doesn’t help Indian patients’ case in all of this is that there is practically no price control on patented cancer drugs that promise higher chances for survival than older drugs. These drugs have been and will continue to be outside the ambit of the price control policy, even though India has amended the Drug Pricing Control Order DPCO in January 2019—the legislation used for capping prices of drugs. The direction the price control policy has taken is evidence that lowering the price of cancer drugs is not a priority.

Cancer drugs can cost as high as Rs 2,11,538 ($2979) (for two months treatment of leukaemia with Dasatinib – with a daily 70 mg tablet). The drug is patented by New York-based Bristol-Myers Squibb and is used for treating leukaemia. About 40% of the oncology drugs market in India is made of patented drugs, says a senior executive with the American pharma major Eli Lily. Patented drugs are new and carry more benefits than risks.


Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at detailing the error or queries.